Extra Renal Synthesis of 1,25-dihydroxyvitamin D and its Health Implications

Original Paper

Abstract

Although the kidney was initially thought to be the sole organ responsible for the production of 1,25(OH)2D3 via its enzyme CYP27b1, it is now appreciated that the expression of CYP27b1 in tissues other than the kidney is wide spread. However, the kidney is the major source for circulating 1,25(OH)2D3. Therefore the existence of the capacity for extra renal 1,25(OH)2D3 production begs the question why, and in particular whether the extra renal production of 1,25(OH)2D3 has physiologic importance. In this chapter this question will be discussed. First a compilation of the extra renal sites for CYP27b1 expression is provided. This is followed by a discussion of the regulation of CYP27b1 expression and activity in extra renal tissues, pointing out that such regulation is tissue specific and different from that of CYP27b1 in the kidney. Finally the physiologic significance of extra renal 1,25(OH)2D3 production is examined, with special focus on the role of CYP27b1 in regulation of cellular proliferation and differentiation, hormone secretion, and immune function. At this point the data do not clearly demonstrate an essential role for CYP27b1 expression in any tissue outside the kidney, but several examples pointing in this direction are provided. With the availability of the mouse enabling tissue-specific deletion of CYP27b1, the role of extra renal CYP27b1 expression can now be addressed definitively.

Keywords

CYP27b1 Proliferation Differentiation Parathyroid hormone Insulin FGF23 Immune function Cancer Keratinocytes Macrophages 

References

  1. 1.
    Fraser DR, Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970;228(5273):764–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Gray TK, et al. Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy. Science. 1979;204(4399):1311–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Weisman Y, et al. 1 alpha, 25-Dihydroxyvitamin D3 and 24, 25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature. 1979;281(5729):317–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Brumbaugh PF, et al. Filter assay for 1alpha, 25-dihydroxyvitamin D3. Utilization of the hormone’s target tissue chromatin receptor. Biochemistry. 1974;13(20):4091–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Reeve L, et al. Studies on the site of 1, 25-dihydroxyvitamin D3 synthesis in vivo. J Biol Chem. 1983;258(6):3615–7.PubMedGoogle Scholar
  6. 6.
    Shultz TD, et al. Do tissues other than the kidney produce 1, 25-dihydroxyvitamin D3 in vivo? A reexamination. Proc Natl Acad Sci USA. 1983;80(6):1746–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Lambert PW, et al. Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest. 1982;69(3):722–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Dusso A, et al. Extra-renal production of calcitriol in chronic renal failure. Kidney Int. 1988;34(3):368–75.PubMedCrossRefGoogle Scholar
  9. 9.
    Littledike ET, Horst RL. Metabolism of vitamin D3 in nephrectomized pigs given pharmacological amounts of vitamin D3. Endocrinology. 1982;111(6):2008–13.PubMedGoogle Scholar
  10. 10.
    Barbour GL, et al. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1, 25-dihydroxyvitamin D. N Engl J Med. 1981;305(8):440–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Turner RT, et al. In vitro synthesis of 1 alpha, 25-dihydroxycholecalciferol and 24, 25-dihydroxycholecalciferol by isolated calvarial cells. Proc Natl Acad Sci USA. 1980;77(10):5720–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Frankel TL, et al. The synthesis of vitamin D metabolites by human melanoma cells. J Clin Endocrinol Metab. 1983;57(3):627–31.PubMedGoogle Scholar
  13. 13.
    Adams JS, Gacad MA. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med. 1985;161(4):755–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Bikle DD, et al. Neonatal human foreskin keratinocytes produce 1, 25-dihydroxyvitamin D3. Biochemistry. 1986;25(7):1545–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Fu GK, et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol. 1997;11(13):1961–70.PubMedCrossRefGoogle Scholar
  16. 16.
    Takeyama K, et al. 25-Hydroxyvitamin D3 1 alpha-hydroxylase and vitamin D synthesis. Science. 1997;277(5333):1827–30.PubMedCrossRefGoogle Scholar
  17. 17.
    St-Arnaud R, et al. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res. 1997;12(10):1552–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Shinki T, et al. Cloning and expression of rat 25-hydroxyvitamin D3-1alpha-hydroxylase cDNA. Proc Natl Acad Sci USA. 1997;94(24):12920–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Zehnder D, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86(2):888–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Panda DK, et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA. 2001;98(13):7498–503.PubMedCrossRefGoogle Scholar
  21. 21.
    Dardenne O, et al. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)- hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology. 2001;142(7):3135–41.PubMedCrossRefGoogle Scholar
  22. 22.
    Delvin EE, et al. In vitro metabolism of 25-hydroxycholecalciferol by isolated cells from human decidua. J Clin Endocrinol Metab. 1985;60(5):880–5.PubMedGoogle Scholar
  23. 23.
    Turner RT, et al. Calvarial cells synthesize 1 alpha, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Biochemistry. 1983;22(5):1073–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Adams JS, et al. Isolation and structural identification of 1, 25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab. 1985;60(5):960–6.PubMedGoogle Scholar
  25. 25.
    Glorieux FH, et al. Pseudo-vitamin D deficiency: absence of 25-hydroxyvitamin D 1 alpha-hydroxylase activity in human placenta decidual cells. J Clin Endocrinol Metab. 1995;80(7):2255–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Bikle DD, et al. Production of 1, 25 dihydroxyvitamin D3 by perfused pig skin. J Invest Dermatol. 1994;102(5):796–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Pillai S, et al. 1, 25-Dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentiation. J Biol Chem. 1988;263(11):5390–5.PubMedGoogle Scholar
  28. 28.
    Milde P, et al. Expression of 1, 25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol. 1991;97(2):230–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Stumpf WE, et al. Topographical and developmental studies on target sites of 1, 25 (OH)2 vitamin D3 in skin. Cell Tissue Res. 1984;238(3):489–96.PubMedCrossRefGoogle Scholar
  30. 30.
    Hsu JY, et al. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001;61(7):2852–6.PubMedGoogle Scholar
  31. 31.
    Chen TC. 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. Anticancer Res. 2008;28(4A):2015–7.PubMedGoogle Scholar
  32. 32.
    Bareis P, et al. 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun. 2001;285(4):1012–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Tangpricha V, et al. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet. 2001;357(9269):1673–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Bises G, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem. 2004;52(7):985–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Segersten U, et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Breast Cancer Res. 2005;7(6):R980–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Friedrich M, et al. Analysis of 25-hydroxyvitamin D3–1alpha-hydroxylase in cervical tissue. Anticancer Res. 2002;22(1A):183–6.PubMedGoogle Scholar
  37. 37.
    Agic A, et al. Relative expression of 1, 25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod Sci. 2007;14(5):486–97.PubMedCrossRefGoogle Scholar
  38. 38.
    Diaz L, et al. Identification of a 25-hydroxyvitamin D3 1alpha-hydroxylase gene transcription product in cultures of human syncytiotrophoblast cells. J Clin Endocrinol Metab. 2000;85(7):2543–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Zehnder D, et al. The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua. Am J Pathol. 2002;161(1):105–14.PubMedGoogle Scholar
  40. 40.
    Fischer D, et al. Metabolism of vitamin D3 in the placental tissue of normal and preeclampsia complicated pregnancies and premature births. Clin Exp Obstet Gynecol. 2007;34(2):80–4.PubMedGoogle Scholar
  41. 41.
    Vigano P, et al. Cycling and early pregnant endometrium as a site of regulated expression of the vitamin D system. J Mol Endocrinol. 2006;36(3):415–24.PubMedCrossRefGoogle Scholar
  42. 42.
    Mitschele T, et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Invest. 2004;84(6):693–702.PubMedCrossRefGoogle Scholar
  43. 43.
    Reichrath J, et al. Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J Cutan Pathol. 2004;31(3):224–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Ogunkolade BW, et al. Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase mRNA in individuals with colorectal cancer. Lancet. 2002;359(9320):1831–2.PubMedCrossRefGoogle Scholar
  45. 45.
    Becker S, et al. Expression of 25 hydroxyvitamin D3–1alpha-hydroxylase in human endometrial tissue. J Steroid Biochem Mol Biol. 2007;103(3–5):771–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Inui N, et al. Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med. 2001;110(9):687–93.PubMedCrossRefGoogle Scholar
  47. 47.
    Barnes PF, et al. Transpleural gradient of 1, 25-dihydroxyvitamin D in tuberculous pleuritis. J Clin Invest. 1989;83(5):1527–32.PubMedCrossRefGoogle Scholar
  48. 48.
    Yokomura K, et al. Increased expression of the 25-hydroxyvitamin D(3)-1alpha-hydroxylase gene in alveolar macrophages of patients with lung cancer. J Clin Endocrinol Metab. 2003;88(12):5704–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Hayes ME, et al. Peritonitis induces the synthesis of 1 alpha, 25-dihydroxyvitamin D3 in macrophages from CAPD patients. FEBS Lett. 1987;220(2):307–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Hayes ME, et al. Differential metabolism of 25-hydroxyvitamin D3 by cultured synovial fluid macrophages and fibroblast-like cells from patients with arthritis. Ann Rheum Dis. 1992;51(2):220–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Abreu MT, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1, 25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53(8):1129–36.PubMedCrossRefGoogle Scholar
  52. 52.
    Karakelides H, et al. Vitamin D-mediated hypercalcemia in slack skin disease: evidence for involvement of extrarenal 25-hydroxyvitamin D 1alpha-hydroxylase. J Bone Miner Res. 2006;21(9):1496–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Dusso AS, et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab. 1991;72(1):157–64.PubMedCrossRefGoogle Scholar
  54. 54.
    Gyetko MR, et al. Monocyte 1 alpha-hydroxylase regulation: induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. J Leukoc Biol. 1993;54(1):17–22.PubMedGoogle Scholar
  55. 55.
    Fritsche J, et al. Regulation of 25-hydroxyvitamin D3–1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvitamin D3 by human dendritic cells. Blood. 2003;102(9):3314–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Weber L, et al. Cultured rat growth plate chondrocytes express low levels of 1alpha-hydroxylase. Recent Results Cancer Res. 2003;164:147–9.PubMedGoogle Scholar
  57. 57.
    Atkins GJ, et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha, 25-dihydroxyvitamin D3. Bone. 2007;40(6):1517–28.PubMedCrossRefGoogle Scholar
  58. 58.
    Bland R, et al. Expression of 25-hydroxyvitamin D3–1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89–90(1–5):121–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Correa P, et al. Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors—new prospects for treatment of hyperparathyroidism with vitamin d. J Clin Endocrinol Metab. 2002;87(12):5826–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Segersten U, et al. 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab. 2002;87(6):2967–72.PubMedCrossRefGoogle Scholar
  61. 61.
    Lauter K, Arnold A. Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism. J Bone Miner Res. 2009;24(1):102–4.PubMedCrossRefGoogle Scholar
  62. 62.
    Schwartz GG, et al. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis. 2004;25(6):1015–26.PubMedCrossRefGoogle Scholar
  63. 63.
    Bailey R, et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes. 2007;56(10):2616–21.PubMedCrossRefGoogle Scholar
  64. 64.
    Khadzkou K, et al. 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem. 2006;54(3):355–61.PubMedCrossRefGoogle Scholar
  65. 65.
    Anderson PH, et al. Co-expression of CYP27B1 enzyme with the 1.5 kb CYP27B1 promoter-luciferase transgene in the mouse. Mol Cell Endocrinol. 2008;285(1–2):1–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Evans KN, et al. Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol. 2004;165(3):807–13.PubMedGoogle Scholar
  67. 67.
    Hibi M, et al. 1, 25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol. 2008;25(1):73–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Hollis BW. 25-Hydroxyvitamin D3–1 alpha-hydroxylase in porcine hepatic tissue: subcellular localization to both mitochondria and microsomes. Proc Natl Acad Sci USA. 1990;87(16):6009–13.PubMedCrossRefGoogle Scholar
  69. 69.
    Takeuchi A, et al. The enzymatic formation of 1 alpha, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3 in the liver of fetal rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1994;109(1):1–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Diesel B, et al. Gene amplification and splice variants of 25-hydroxyvitamin D3 1, alpha-hydroxylase (CYP27B1) in glioblastoma multiforme—a possible role in tumor progression? Recent Results Cancer Res. 2003;164:151–5.PubMedGoogle Scholar
  71. 71.
    Gao XH, et al. Basal and parathyroid hormone induced expression of the human 25-hydroxyvitamin D 1alpha-hydroxylase gene promoter in kidney AOK-B50 cells: role of Sp1, Ets and CCAAT box protein binding sites. Int J Biochem Cell Biol. 2002;34(8):921–30.PubMedCrossRefGoogle Scholar
  72. 72.
    Strom TM, Juppner H. PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens. 2008;17(4):357–62.PubMedCrossRefGoogle Scholar
  73. 73.
    Kim MS, et al. 1alpha, 25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Mol Cell Endocrinol. 2007;265–266:168–73.PubMedCrossRefGoogle Scholar
  74. 74.
    Bajwa A, et al. Specific regulation of CYP27B1 and VDR in proximal versus distal renal cells. Arch Biochem Biophys. 2008;477(1):33–42.PubMedCrossRefGoogle Scholar
  75. 75.
    Bikle DD, et al. 1, 25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest. 1986;78(2):557–66.PubMedCrossRefGoogle Scholar
  76. 76.
    Flanagan JN, et al. Regulation of the 25-hydroxyvitamin D-1alpha-hydroxylase gene and its splice variant. Recent Results Cancer Res. 2003;164:157–67.PubMedGoogle Scholar
  77. 77.
    Xie Z, et al. The mechanism of 1, 25-dihydroxyvitamin D(3) autoregulation in keratinocytes. J Biol Chem. 2002;277(40):36987–90.PubMedCrossRefGoogle Scholar
  78. 78.
    Bikle DD, et al. Tumor necrosis factor-alpha regulation of 1, 25-dihydroxyvitamin D production by human keratinocytes. Endocrinology. 1991;129(1):33–8.PubMedGoogle Scholar
  79. 79.
    Bikle DD, et al. Regulation of 1, 25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology. 1989;124(2):655–60.PubMedGoogle Scholar
  80. 80.
    Pryke AM, et al. Tumor necrosis factor-alpha induces vitamin D-1-hydroxylase activity in normal human alveolar macrophages. J Cell Physiol. 1990;142(3):652–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Stoffels K, et al. Immune regulation of 25-hydroxyvitamin-D3–1alpha-hydroxylase in human monocytes. J Bone Miner Res. 2006;21(1):37–47.PubMedCrossRefGoogle Scholar
  82. 82.
    Overbergh L, et al. Immune regulation of 25-hydroxyvitamin D-1alpha-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-gamma-mediated induction. J Clin Endocrinol Metab. 2006;91(9):3566–74.PubMedCrossRefGoogle Scholar
  83. 83.
    Adams JS, et al. Regulated production and intracrine action of 1, 25-dihydroxyvitamin D3 in the chick myelomonocytic cell line HD-11. Endocrinology. 1994;134(6):2567–73.PubMedCrossRefGoogle Scholar
  84. 84.
    Ren S, et al. Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1, 25-dihydroxyvitamin D synthesis. J Biol Chem. 2005;280(21):20604–11.PubMedCrossRefGoogle Scholar
  85. 85.
    Wu S, et al. Splice variants of the CYP27b1 gene and the regulation of 1, 25-dihydroxyvitamin D3 production. Endocrinology. 2007;148(7):3410–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Bikle DD, Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr Rev. 1993;14:3–19.PubMedGoogle Scholar
  87. 87.
    Oda Y, et al. Two distinct coactivators, DRIP/Mediator and SRC/p160, are differentially involved in VDR transactivation during keratinocyte differentiation. Mol Endocrinol. 2003;17:2329–39.PubMedCrossRefGoogle Scholar
  88. 88.
    Hawker NP, et al. Regulation of human epidermal keratinocyte differentiation by the vitamin d receptor and its coactivators DRIP205, SRC2, and SRC3. J Invest Dermatol. 2007;127:874.PubMedCrossRefGoogle Scholar
  89. 89.
    Bikle DD, et al. 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest Dermatol. 2004;122(4):984–92.PubMedCrossRefGoogle Scholar
  90. 90.
    Bruce S, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol. 1994;31(5 Pt 1):755–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Bagot M, et al. Immunosuppressive effects of 1, 25-dihydroxyvitamin D3 and its analogue calcipotriol on epidermal cells. Br J Dermatol. 1994;130(4):424–31.PubMedCrossRefGoogle Scholar
  92. 92.
    Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res. 1990;282(3):164–7.PubMedCrossRefGoogle Scholar
  93. 93.
    Garland C, et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet. 1985;1(8424):307–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Bostick RM, et al. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women’s Health Study. Am J Epidemiol. 1993;137(12):1302–17.PubMedGoogle Scholar
  95. 95.
    Kearney J, et al. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am J Epidemiol. 1996;143(9):907–17.PubMedGoogle Scholar
  96. 96.
    Garland FC, et al. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 1990;19(6):614–22.PubMedCrossRefGoogle Scholar
  97. 97.
    Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 1992;70(12):2861–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Ingraham BA, et al. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin. 2008;24(1):139–49.PubMedGoogle Scholar
  99. 99.
    Palmer HG, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001;154(2):369–87.PubMedCrossRefGoogle Scholar
  100. 100.
    Shah S, et al. Trans-repression of beta-catenin activity by nuclear receptors. J Biol Chem. 2003;278(48):48137–45.PubMedCrossRefGoogle Scholar
  101. 101.
    Shah S, et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell. 2006;21(6):799–809.PubMedCrossRefGoogle Scholar
  102. 102.
    Zinser GM, et al. Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis. 2002;23(12):2103–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Ellison TI, et al. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. J Invest Dermatol. 2008;128:2508–17.PubMedCrossRefGoogle Scholar
  104. 104.
    Palmer HG, et al. The vitamin D receptor is a Wnt effector that controls hair follicle differentiation and specifies tumor type in adult epidermis. PLoS ONE. 2008;3(1):e1483.PubMedCrossRefGoogle Scholar
  105. 105.
    Dixon KM, et al. Skin cancer prevention: a possible role of 1, 25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol. 2005;97(1–2):137–43.PubMedCrossRefGoogle Scholar
  106. 106.
    Moll PR, et al. Expression profiling of vitamin D treated primary human keratinocytes. J Cell Biochem. 2007;100(3):574–92.PubMedCrossRefGoogle Scholar
  107. 107.
    Lappe JM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586–91.PubMedGoogle Scholar
  108. 108.
    Beer TM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol. 2007;25(6):669–74.PubMedCrossRefGoogle Scholar
  109. 109.
    Vieth R, et al. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003;88(1):185–91.PubMedCrossRefGoogle Scholar
  110. 110.
    Demay MB, et al. Sequences in the human parathyroid hormone gene that bind the 1, 25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA. 1992;89(17):8097–101.PubMedCrossRefGoogle Scholar
  111. 111.
    Martin KJ, Gonzalez EA. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol. 2004;24(5):456–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1, 25-dihydroxyvitamin D. J Biol Chem. 2002;277(33):30337–50.PubMedCrossRefGoogle Scholar
  113. 113.
    Pittas AG, et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017–29.PubMedCrossRefGoogle Scholar
  114. 114.
    Kadowaki S, Norman AW. Demonstration that the vitamin D metabolite 1, 25(OH)2-vitamin D3 and not 24R, 25(OH)2-vitamin D3 is essential for normal insulin secretion in the perfused rat pancreas. Diabetes. 1985;34(4):315–20.PubMedCrossRefGoogle Scholar
  115. 115.
    Lee S, et al. 1, 25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology. 1994;134(4):1602–10.PubMedCrossRefGoogle Scholar
  116. 116.
    Kolek OI, et al. 1alpha, 25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005;289(6):G1036–42.PubMedCrossRefGoogle Scholar
  117. 117.
    Chen S, et al. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179(3):1634–47.PubMedGoogle Scholar
  118. 118.
    Rigby WF, et al. Inhibition of T lymphocyte mitogenesis by 1, 25-dihydroxyvitamin D3 (calcitriol). J Clin Invest. 1984;74(4):1451–5.PubMedCrossRefGoogle Scholar
  119. 119.
    Lemire JM, et al. Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125(6 Suppl):1704S–8S.PubMedGoogle Scholar
  120. 120.
    Daniel C, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324(1):23–33.PubMedCrossRefGoogle Scholar
  121. 121.
    Boonstra A, et al. 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001;167(9):4974–80.PubMedGoogle Scholar
  122. 122.
    Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164(5):2405–11.PubMedGoogle Scholar
  123. 123.
    Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol. 2005;233(2):115–24.PubMedCrossRefGoogle Scholar
  124. 124.
    Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 2001;15(14):2579–85.PubMedCrossRefGoogle Scholar
  125. 125.
    Ponsonby AL, et al. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology. 2002;181–182:71–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Hypponen E, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358(9292):1500–3.PubMedCrossRefGoogle Scholar
  127. 127.
    Munger KL, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–8.PubMedCrossRefGoogle Scholar
  128. 128.
    Litonjua AA, Weiss ST. Is vitamin D deficiency to blame for the asthma epidemic? J Allergy Clin Immunol. 2007;120(5):1031–5.PubMedCrossRefGoogle Scholar
  129. 129.
    Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449(7164):819–26.PubMedCrossRefGoogle Scholar
  130. 130.
    Gombart AF, et al. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067–77.PubMedCrossRefGoogle Scholar
  131. 131.
    Wang TT, et al. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–12.PubMedGoogle Scholar
  132. 132.
    Ustianowski A, et al. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. J Infect. 2005;50(5):432–7.PubMedCrossRefGoogle Scholar
  133. 133.
    Rook GA, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology. 1986;57(1):159–63.PubMedGoogle Scholar
  134. 134.
    Liu PT, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–3.PubMedCrossRefGoogle Scholar
  135. 135.
    Schauber J, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803–11.PubMedCrossRefGoogle Scholar
  136. 136.
    van Driel M, et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J. 2006;20(13):2417–9.PubMedCrossRefGoogle Scholar
  137. 137.
    Jones G, et al. Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology. 1999;140(7):3303–10.PubMedCrossRefGoogle Scholar
  138. 138.
    Davies M, et al. Abnormal vitamin D metabolism in Hodgkin’s lymphoma. Lancet. 1985;1(8439):1186–8.PubMedCrossRefGoogle Scholar
  139. 139.
    Adams JS, et al. Hypercalcemia, hypercalciuria, and elevated serum 1, 25 dihydroxyvitamin D concentrations in patients with AIDS and non-AIDS associated lymphoma. Blood. 1979;73:235–9.Google Scholar
  140. 140.
    Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphomas. Blood. 1993;82(5):1383–94.PubMedGoogle Scholar
  141. 141.
    Mawer EB, et al. Constitutive synthesis of 1, 25-dihydroxyvitamin D3 by a human small cell lung cancer cell line. J Clin Endocrinol Metab. 1994;79(2):554–60.PubMedCrossRefGoogle Scholar
  142. 142.
    Maas RM, et al. Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1, alpha-hydroxylase (CYP 27B1) in human malignant glioma. Clin Cancer Res. 2001;7(4):868–75.PubMedGoogle Scholar
  143. 143.
    Lechner D, et al. 1alpha, 25-dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in colon cells. Mol Cell Endocrinol. 2007;263(1–2):55–64.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  1. 1.Veterans Affairs Medical CenterUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations